"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 4 | 4 |
| 2001 | 4 | 9 | 13 |
| 2002 | 2 | 3 | 5 |
| 2003 | 0 | 7 | 7 |
| 2004 | 2 | 9 | 11 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 14 | 14 |
| 2008 | 2 | 15 | 17 |
| 2009 | 0 | 16 | 16 |
| 2010 | 0 | 17 | 17 |
| 2011 | 0 | 19 | 19 |
| 2012 | 0 | 13 | 13 |
| 2013 | 0 | 11 | 11 |
| 2014 | 5 | 5 | 10 |
| 2015 | 1 | 13 | 14 |
| 2016 | 2 | 14 | 16 |
| 2017 | 3 | 15 | 18 |
| 2018 | 0 | 21 | 21 |
| 2019 | 7 | 15 | 22 |
| 2020 | 4 | 4 | 8 |
| 2021 | 3 | 9 | 12 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 14 | 14 |
| 2025 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 Dec 01; 8(12):e2549109.
-
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Nov 01; 117(11):2388-2393.
-
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. Ann Oncol. 2025 Nov; 36(11):1356-1365.
-
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Sep; 23(9):403-418.
-
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). Eur J Cancer. 2025 Sep 09; 227:115694.
-
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma. Gastroenterology. 2025 Sep; 169(4):585-599.
-
Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes. Gynecol Oncol. 2025 May; 196:85-91.
-
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 May; 32(5):3278-3291.
-
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2025 Apr; 135(4):621-628.
-
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.